Consequently, combining multiple medications, such as PD-1 with 4-1BB, or Programmed death-ligand 1 (PD-L1) with 4-1BB, to improve the safety and efficacy of cancer therapies is an alternative novel cancer immunotherapy strategy.4, 13, 29. The gene discussed is CD274; the disease is cancer.